Ryan J O Dowling
Overview
Explore the profile of Ryan J O Dowling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
2458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodwin P, Dowling R, Ennis M, Chen B, Parulekar W, Shepherd L, et al.
JNCI Cancer Spectr
. 2021 Sep;
5(5).
PMID: 34485814
Background: Circulating levels of cancer antigen (CA) 15-3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of...
2.
Goodwin P, Dowling R, Ennis M, Chen B, Parulekar W, Shepherd L, et al.
NPJ Breast Cancer
. 2021 Jun;
7(1):74.
PMID: 34103538
Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether...
3.
Pimentel I, Chen B, Lohmann A, Ennis M, Ligibel J, Shepherd L, et al.
J Natl Cancer Inst
. 2021 Feb;
113(2):192-198.
PMID: 33527137
Background: Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex...
4.
Dowling R, Kalinsky K, Hayes D, Bidard F, Cescon D, Chandarlapaty S, et al.
JNCI Cancer Spectr
. 2020 Apr;
3(4):pkz050.
PMID: 32337479
Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original...
5.
Dowling R, Sparano J, Goodwin P, Bidard F, Cescon D, Chandarlapaty S, et al.
JNCI Cancer Spectr
. 2020 Apr;
3(4):pkz049.
PMID: 32337478
Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened...
6.
Stambolic V, Dowling R
JNCI Cancer Spectr
. 2020 Mar;
4(1):pkz097.
PMID: 32206745
No abstract available.
7.
Ho J, Cruise E, Dowling R, Stambolic V
Cold Spring Harb Perspect Med
. 2019 Nov;
10(5).
PMID: 31712221
For years, clinical and basic researchers have been aware of the presence of PTEN in the nucleus in cell culture, animal models, and both healthy and diseased human tissues. Despite...
8.
Pimentel I, Lohmann A, Ennis M, Dowling R, Cescon D, Elser C, et al.
Breast
. 2019 Sep;
48:17-23.
PMID: 31472446
Objectives: Pre-clinical data suggest metformin might enhance the effect of chemotherapy in breast cancer (BC). We conducted a Phase II randomized trial of chemotherapy plus metformin versus placebo in metastatic...
9.
Ligibel J, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, et al.
Clin Cancer Res
. 2019 Apr;
25(17):5398-5406.
PMID: 31018921
Purpose: Exercise after breast cancer diagnosis is associated with lower cancer-specific mortality, but the biological mechanisms through which exercise impacts breast cancer are not fully understood. The Pre-Operative Health and...
10.
Lohmann A, Dowling R, Ennis M, Amir E, Elser C, Brezden-Masley C, et al.
JNCI Cancer Spectr
. 2018 Jul;
2(2):pky028.
PMID: 30035251
Background: Circulating tumor cells (CTCs) are associated with worse prognosis in metastatic breast cancer (BC). We evaluated the association of metabolic, inflammatory, and tumor markers with CTCs in women with...